Compare Adobe Systems Inc (ADBE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Gilead Sciences, Inc. — how do they compare? Adobe Systems Inc trades at $220.8 (market cap $88.06B), while Gilead Sciences, Inc. trades at $135.25 (market cap $169.30B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | GILD | |
|---|---|---|
Market Cap | $88.06B | $169.30B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $155.80 |
52-Week Low | $193.41 | $108.22 |
Enterprise Value | $89.50B | $183.83B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.92, up 1.31% with a bullish technical signal despite recent volatility. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $5.96 versus $5.82, revenue growth to $23.77B in 2025, and robust profitability margins. However, negative net cash flow of -$2.18B in 2025 and AI competition concerns from recent news create mixed sentiment.
Outlook remains positive with a consensus price target of $246.75, representing 11.7% upside, supported by 49.21% analyst buy ratings. Key risks include AI disruption fears and CEO transition uncertainty, but Adobe's entrenched market position and double-digit growth provide a solid foundation for long-term investors.
Gilead Sciences (GILD) trades at $136.36, up 3.88% today and 25.2% over the past year, showing strong momentum. The stock exhibits bullish technical signals with support at $128 and resistance at $136. Fundamentally, GILD maintains robust profitability with a 30.99% net margin and has beaten earnings estimates for three consecutive quarters. Recent FDA and EC approvals for Trodelvy's expanded use in metastatic triple-negative breast cancer provide significant growth catalysts.
GILD presents a compelling investment case with strong analyst support (65.5% buy ratings) and a $156.14 consensus price target offering 14.5% upside. Key risks include generic competition for dolutegravir and execution challenges in oncology growth. The company's solid cash flow generation and expanding product portfolio support continued shareholder value creation despite recent negative net cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
